

CITATION REPORT

List of articles citing

Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden

DOI: 10.1111/j.1742-1241.2007.01415.x

International Journal of Clinical Practice, 2007, 61, 1181-7.

Source: <https://exaly.com/paper-pdf/42910328/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
265	[Opioid-induced bowel dysfunction: a literature analysis on pathophysiology and treatment]. 2008 , 158, 621-6		6
264	Current awareness: Pharmacoepidemiology and drug safety. 2008 , 17, i-xii		
263	Gastrointestinal side effects in chronic opioid users: results from a population-based survey. 2008 , 27, 1224-32		114
262	Palliative care and pain: new strategies for managing opioid bowel dysfunction. 2008 , 11 Suppl 1, S1-19; quiz S21-2		25
261	Sex differences in micro-opioid receptor expression in the rat midbrain periaqueductal gray are essential for eliciting sex differences in morphine analgesia. 2008 , 28, 14007-17		107
260	Prevalence of opioid dispensings and concurrent gastrointestinal medications in Quebec. 2008 , 13, 395-400		6
259	Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation. 2010 , 4, 247-58		16
258	Effect of bisphosphonates on pain and quality of life in patients with bone metastases. 2009 , 6, 163-74		124
257	Methylnaltrexone: a novel approach for the management of opioid-induced constipation in patients with advanced illness. 2009 , 3, 473-85		14
256	Opioid bowel dysfunction and narcotic bowel syndrome: a population-based study. 2009 , 104, 1199-204		41
255	Recent Advances in Pharmacotherapy. 2009 , 22, 446-466		
254	[Methylnaltrexone. A new approach for therapy of opioid-induced obstipation]. 2009 , 23, 471-8		4
253	Opioidinduzierte Obstipation. Aktuelle Therapiemöglichkeiten in der palliativen Schmerztherapie. 2009 , 3, 18-21		
252	Implementing the SAFE Principles for the Development of Pain Medicine Therapeutic Algorithms That Include Neuromodulation Techniques. 2009 , 12, 104-13		29
251	Oxymorphone and Opioid Rotation. 2009 , 10, S39-S48		0
250	mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). 2009 , 19, 5679-83		7
249	Constipation induite par les opioïdes: État des lieux et nouvelles approches. 2009 , 10, 237-243		1

248	Recommandations pour la prévention et le traitement de la constipation induite par les opioïdes chez le patient relevant de soins palliatifs. 2009 , 8, S5-S33		4
247	European perspectives on pain and palliative care. 2009 , 23, 182-97		1
246	Targino® recibe la aprobación europea para controlar el dolor crónico intenso. 2009 , 16, 256-257		
245	Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. 2009 , 373, 1198-206	91	
244	Opioid antagonists for prevention and treatment of opioid-induced gastrointestinal effects. 2010 , 23, 616-22		41
243	Drug-induced acute liver failure and gastrointestinal complications. 2010 , 38, S175-87		17
242	Opioid analgesics and narcotic antagonists. 2010 , 32, 183-224		1
241	Akutes Abdomen. 2010 , 47, 225-234		
240	Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation. <i>Advances in Therapy</i> , 2010 , 27, 581-90	4.1	20
239	Antagonistes opioïdes et constipation. 2010 , 23, 182-188		
238	Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. 2010 , 55, 2912-21		113
237	The direct and indirect costs of opioid-induced constipation. 2010 , 40, 696-703		66
236	Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. 2010 , 22, 424-30, e96		131
235	Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain. 2010 , 44, 630-40		45
234	Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. 2010 , 26, 1377-87		57
233	Quality of life in relation to constipation among opioid users. 2010 , 13, 129-35		35
232	Opioid therapy for osteoarthritis and chronic low back pain. 2010 , 122, 87-97		8
231	Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. 2010 , 11, 1787-804		185

230	Comparison of two bowel treatments to prevent constipation in post-surgical orthopaedic patients. 2010 , 14, 75-81		6
229	Pharmacological treatment of chronic pain - the need for CHANGE. 2010 , 26, 1231-45		97
228	Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?. 2010 , 26, 1677-84		31
227	The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. 2011 , 39, 41-50		80
226	Caractéristiques cliniques des douleurs cancéreuses liées chez les patients traités par oxycodone. Cohorte OCS2. 2011 , 12, 110-122		1
225	Morphine induces μ opioid receptor endocytosis in guinea pig enteric neurons following prolonged receptor activation. 2011 , 140, 618-26		33
224	Health care resource use and costs in opioid-treated patients with and without constipation in Brazil. 2011 , 14, S78-81		7
223	Attitude of Swiss physicians towards opioid-induced constipation: a national survey. 2011 , 22, 527-31		6
222	Novel opioid antagonists for opioid-induced bowel dysfunction. 2011 , 20, 1047-56		57
221	Pharmacoeconomic impact of adverse events of long-term opioid treatment for the management of persistent pain. <i>Clinical Drug Investigation</i> , 2011 , 31, 73-86	3.2	24
220	A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. 2011 , 12, 175-84		53
219	The mystery of opioid-induced diarrhea. 2011 , 16, 197-9		8
218	Case-controlled study on risk factors for the development of constipation in hospitalized patients. 2011 , 131, 469-76		15
217	Using the SAFE principles when evaluating electrical stimulation therapies for the pain of failed back surgery syndrome. 2011 , 14, 299-311; discussion 311		44
216	Biopsychosocial assessment criteria for functional chronic visceral pain: a pilot review of concept and practice. 2011 , 12, 552-64		4
215	Pharmacologic management of cancer-related pain, dyspnea, and nausea. 2011 , 38, 450-9		14
214	The solution-phase design and synthesis of libraries for the discovery of CNS active substances. 2011 , 16, 742-744		
213	Validated tools for evaluating opioid-induced bowel dysfunction. <i>Advances in Therapy</i> , 2011 , 28, 279-94	4.1	24

212	Methylnaltrexone: treatment for opioid-induced constipation. 2011 , 28, 59-61	7
211	Neostigmine for the treatment of gastrointestinal atony: a report of one case. 2011 , 14, 1270-3	4
210	Assessing constipation in palliative care within a gastroenterology framework. 2012 , 26, 834-41	11
209	A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. 2012 , 26, 50-60	119
208	The Bowel Function Index: a new validated scale for assessing opioid-induced constipation. 2012 , 28, 457-66	27
207	Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. 2012 , 343, 277-80	38
206	Efficacy and tolerability of oxycodone in moderate-severe cancer-related pain: A meta-analysis of randomized controlled trials. 2012 , 4, 249-254	9
205	Análisis económico de oxycodona LP/ naloxona LP en el manejo del dolor intenso y el estreñimiento asociado al tratamiento con opioides en España. 2012 , 9, 23-34	
204	Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. 2012 , 15, 564-75	43
203	Opioid-induced bowel dysfunction: pathophysiology and management. 2012 , 72, 1847-65	144
202	Evolution of topical NSAIDs in the guidelines for treatment of osteoarthritis in elderly patients. 2012 , 29, 523-31	26
201	Effects of methylnaltrexone on guinea pig gastrointestinal motility. 2013 , 386, 279-86	3
200	Opioid induced bowel disease: a twenty-first century physicians dilemma. Considering pathophysiology and treatment strategies. 2013 , 15, 334	28
199	Treatment of opioid-induced constipation: focus on the peripheral opioid receptor antagonist methylnaltrexone. 2013 , 73, 1297-306	20
198	Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers. 2013 , 35, 1876-83	26
197	Spinal cord stimulation as treatment for complex regional pain syndrome should be considered earlier than last resort therapy. 2013 , 16, 125-41	56
196	Peripherally acting novel lipo-endorphin-1 peptides in neuropathic pain without producing constipation. 2013 , 21, 1898-904	16
195	Il controllo del dolore nelle protesi totali di ginocchio. 2013 , 27, 147-152	

194	Combined oral prolonged-release oxycodone and naloxone in chronic pain management. 2013 , 22, 161-6	28
193	Associations between medication use and functional gastrointestinal disorders: a population-based study. 2013 , 25, 413-9, e298	16
192	Patients receiving opioids for pain usually require additional pharmacological treatment for opioid-induced constipation. 2013 , 29, 117-121	
191	Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. 2013 , 29, 1399-409	56
190	Clinical heterogeneity in patients with the hypermobility type of Ehlers-Danlos syndrome. 2013 , 34, 873-81	52
189	Constipation in palliative care: what do we use as definitions and outcome measures?. 2013 , 45, 753-62	15
188	A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. 2013 , 154, 1542-1550	94
187	Palliation of Nonpain Symptoms. 2013 , 2, e437-e455	
186	Ligand-induced μ opioid receptor internalization in enteric neurons following chronic treatment with the opiate fentanyl. 2013 , 91, 854-60	8
185	Overview and treatment of opioid-induced constipation. 2013 , 125, 7-17	10
184	Current guidelines for the management of constipation. 2013 , 190-207	
183	Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. 2013 , 16, 1423-33	62
182	A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. 2013 , 27, 447-56	35
181	Recovering a fecal habitus: analyzing heroin users' toilet talk. 2013 , 32, 95-108	3
180	Opioids. 2013 , 1283-1288	1
179	What Medications Are Effective in Preventing and Relieving Constipation in the Setting of Opioid Use?. 2013 , 129-134	
178	Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. 2014 , 6, 269-81	82
177	Patient preferences for change in symptoms associated with opioid-induced constipation. <i>Advances in Therapy</i> , 2014 , 31, 1263-71	4.1 13

176	Opioid-induced constipation: pathophysiology, clinical consequences, and management. 2014 , 2014, 141737		90
175	Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives. 2014 , 30, 2389-96		20
174	In-hospital costs associated with chronic constipation in Belgium: a retrospective database study. 2014 , 26, 368-76		11
173	Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. 2014 , 40, 771-9		82
172	Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. 2014 , 26, 1386-95		139
171	Effectiveness and tolerability of low-dose oral oxycodone/naloxone added to anticonvulsant therapy for noncancer neuropathic pain: an observational analysis. 2014 , 30, 555-64		10
170	Prevalence and types of rectal douches used for anal intercourse: results from an international survey. 2014 , 14, 95		28
169	Opioid induced nausea and vomiting. 2014 , 722, 67-78		80
168	[Observational and cross-sectional study of prevalence and severity of the opioid-induced bowel dysfunction]. 2014 , 46, 32-9		8
167	Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials. <i>Advances in Therapy</i> , 2014 , 31, 604-20	4.1	12
166	Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach. 2014 , 2, 31-7		77
165	Patient preference with respect to QoL and reduction in opioid-induced constipation (OIC) after treatment with prolonged-release (PR) oxycodone/naloxone compared with previous analgesic therapy [PREFER study]. <i>International Journal of Clinical Practice</i> , 2014 , 68, 1364-75	2.9	10
164	Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone. <i>BMC Palliative Care</i> , 2014 , 13, 42	3	12
163	Bladder and bowel symptoms among adults presenting with low back pain to an academic chiropractic clinic: results of a preliminary study. 2014 , 13, 178-87		2
162	Reducing the burden of postoperative ileus: evaluating and implementing an evidence-based strategy. 2014 , 38, 1966-77		43
161	Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. <i>Clinical Drug Investigation</i> , 2014 , 34, 501-11	3.2	31
160	Diagnosis and treatment of narcotic bowel syndrome. 2014 , 11, 410-8		34
159	[Analysis of constipation in severe trauma patients]. 2014 , 25, 46-51		6

158	Naloxegol for opioid-induced constipation in patients with noncancer pain. 2014 , 370, 2387-96		243
157	Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. 2014 , 49, 24-45		109
156	Case Studies in Pain Management. 373-378		
155	Case Studies in Pain Management. 467-472		
154	Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study. 2015 , 4, 434-41		18
153	Opioid-Induced Constipation Among Patients with Chronic Noncancer Pain in the United States, Canada, Germany, and the United Kingdom: Laxative Use, Response, and Symptom Burden Over Time. 2015 , 16, 1551-65		55
152	Prescribing in end of life care. 2015 , 8, 340-347		1
151	The impact of opioid-induced constipation among chronic pain patients with sufficient laxative use. <i>International Journal of Clinical Practice</i> , 2015 , 69, 1448-56	2.9	20
150	Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol. 2015 , 4, 442-8		9
149	Developments in managing severe chronic pain: role of oxycodone-naloxone extended release. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 3811-6	4.4	3
148	Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids. 2015 , 8, 459-75		9
147	Cauda Equina Syndrome and the challenge of diagnosis for physiotherapists: A review. 2015 , 36, 81-86		3
146	Morphine for the treatment of pain in sickle cell disease. 2015 , 2015, 540154		32
145	Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation. 2015 , 37, 784-92		30
144	Tapentadol extended release in the management of peripheral diabetic neuropathic pain. 2015 , 11, 95-105		31
143	New Formulation of Sustained Release Naloxone Can Reverse Opioid Induced Constipation Without Compromising the Desired Opioid Effects. 2015 , 16, 1540-50		17
142	Opioid-Induced Constipation. 2015 , 16 Suppl 1, S16-21		44
141	Impact of prolonged-release oxycodone/naloxone on outcomes affecting patientsQdaily functioning in comparison with extended-release tapentadol: a systematic review. 2015 , 37, 212-24		12

140	Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. 2015 , 37, 94-113		25
139	Postoperative ileus: Recent developments in pathophysiology and management. 2015 , 34, 367-76		189
138	Naloxegol , a new drug for the treatment of opioid-induced constipation. 2015 , 16, 399-406		22
137	Assessment of a Stool Symptom Screener and Understanding the Opioid-Induced Constipation Symptom Experience. 2015 , 8, 317-27		12
136	Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone. <i>Clinical Drug Investigation</i> , 2015 , 35, 1-11	3.2	29
135	A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy. <i>Clinical Drug Investigation</i> , 2015 , 35, 95-108	3.2	30
134	Novel endomorphin-1 analogs with C-terminal oligoarginine-conjugation display systemic antinociceptive activity with less gastrointestinal side effects. 2015 , 116, 24-33		11
133	Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations. 2015 , 31, 1413-29		26
132	Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. <i>Supportive Care in Cancer</i> , 2015 , 23, 823-30	3.9	47
131	Management of severe pain due to lumbar disk protrusion. 2015 , 29, 64-5; discussion 65-6		1
130	Hospice and Palliative Nurses Association 2015-2018 Research Agenda. 2015 , 17, 119-127		6
129	Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial. 2015 , 37, 2420-38		30
128	Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension. 2015 , 18, 593-600		43
127	Advances in pharmacotherapy for opioid-induced constipation - a systematic review. 2015 , 16, 515-32		18
126	Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes. 2016 , 12, 401-12		25
125	Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations. 2016 , 9, 1001-1020		14
124	The Effect of DA-9701 in Opioid-induced Bowel Dysfunction of Guinea Pig. 2016 , 22, 529-38		8
123	Satisfaction with Therapy Among Patients with Chronic Noncancer Pain with Opioid-Induced Constipation. 2016 , 22, 246-53		15

122	Opioid-Induced Constipation among a Convenience Sample of Patients with Cancer Pain. 2016 , 6, 131		15
121	Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments. 2016 , 7, 414		95
120	Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline. 2017 , 18, 1837-1863		82
119	The Dutch Central Sensitization Inventory (CSI): Factor Analysis, Discriminative Power, and Test-Retest Reliability. <i>Clinical Journal of Pain</i> , 2016 , 32, 624-30	3.5	88
118	Preoperative bowel preparation versus no preparation before spinal surgery: A randomised clinical trial. 2016 , 23, 3-13		5
117	Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility. <i>Advances in Therapy</i> , 2016 , 33, 1331-46	4.1	2
116	Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial. 2016 , 16, 600-19		45
115	Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients. 2016 , 81, 89-100		23
114	Constipation in Elderly Patients with Noncancer Pain: Focus on Opioid-Induced Constipation. 2016 , 33, 557-74		32
113	Laxative utilization over time in chronic pain patients with opioid-induced constipation. <i>Pain Management</i> , 2016 , 6, 531-541	2.3	4
112	Laxatives Do Not Improve Symptoms of Opioid-Induced Constipation: Results of a Patient Survey. 2017 , 18, 1932-1940		27
111	Opioid receptor agonists. 2016 , 348-380		
110	Population Exposure-Response Modeling of Naloxegol in Patients With Noncancer-Related Pain and Opioid-Induced Constipation. 2016 , 5, 359-66		7
109	Measuring quality of life in opioid-induced constipation: mapping EQ-5D-3 L and PAC-QOL. 2016 , 6, 14		12
108	Opioid-induced constipation, use of laxatives, and health-related quality of life. 2016 , 11, 104-110		30
107	Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada. 2016 , 19, 277-91		11
106	Adjusting Bowel Regimens When Prescribing Opioids in Women Receiving Palliative Care in the Acute Care Setting. 2016 , 33, 663-8		2
105	The efficacy of standard laxative use for the prevention and treatment of opioid induced constipation during oxycodone use: a small Dutch observational pilot study. 2016 , 10, 547-53		9

104	Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study. 2016 , 16, 580-99	49
103	Pharmacological treatment for antipsychotic-related constipation. 2017 , 1, CD011128	16
102	Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study. 2017 , 21, 1485-1494	14
101	Identifying Factors That Predict Worse Constipation Symptoms in Palliative Care Patients: A Secondary Analysis. 2017 , 20, 528-532	2
100	Pharmacometric Modeling of Naloxegol Efficacy and Safety: Impact on Dose and Label. 2017 , 102, 741-744	8
99	Reliability and validity of the Bowel Function Index for evaluating opioid-induced constipation: translation, cultural adaptation and validation of the Portuguese version (BFI-P). 2017 , 33, 563-572	4
98	Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting μ -Opioid Receptor Antagonist. 2017 , 56, 573-582	8
97	Opioid-induced constipation: reflections on efficacy assessment. 2017 , 2, 540-541	1
96	Population Exposure-Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid-Induced Constipation. 2017 , 6, 705-711	2
95	Prolonged release oxycodone and naloxone treatment counteracts opioid-induced constipation in patients with severe pain compared to previous analgesic treatment. 2017 , 33, 2217-2227	2
94	Prokinetic effects of LD02GIFRO on functional gastrointestinal disorder in rats. 2017 , 13, 2043-2049	2
93	Addressing Opioid-Associated Constipation Using Quality Oncology Practice Initiative Scores and Plan-Do-Study-Act Cycles. 2017 , 13, e91-e97	4
92	Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer. 2017 , 35, 1921-1928	34
91	Prevalence and Clinical Outcomes of Common Bile Duct Dilation in Patients Who Use Opium. 2018 , 356, 39-46	0
90	Updates in palliative care - recent advancements in the pharmacological management of symptoms. 2018 , 18, 11-16	8
89	The impact of naloxegol on anal sphincter function - Using a human experimental model of opioid-induced bowel dysfunction. 2018 , 117, 187-192	11
88	Investigational opioid antagonists for treating opioid-induced bowel dysfunction. 2018 , 27, 235-242	5
87	Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid-Induced Constipation. 2018 , 18, 505-514	9

86	The Efficacy and Safety of Transcutaneous Acupoint Interferential Current Stimulation for Cancer Pain Patients With Opioid-Induced Constipation: A Prospective Randomized Controlled Study. 2018 , 17, 437-443	6
85	Risk factors of opioid-induced adverse reactions in elderly male outpatients of Korea Veterans Hospital. 2018 , 18, 293	8
84	Incidence and Health Related Quality of Life of Opioid-Induced Constipation in Chronic Noncancer Pain Patients: A Prospective Multicentre Cohort Study. 2018 , 2018, 5704627	12
83	Prolonged-release oxycodone/naloxone reduces opioid-induced constipation and improves quality of life in laxative-refractory patients: results of an observational study. 2018 , 11, 57-67	5
82	Transversus Abdominis Plane Blockade as Part of a Multimodal Postoperative Analgesia Plan in Patients Undergoing Radical Cystectomy. 2018 , 4, 161-167	16
81	Resource use and costs associated with opioid-induced constipation following total hip or total knee replacement surgery. 2018 , 11, 1017-1025	15
80	Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care. 2018 , 6, CD006332	16
79	Enkephalins and ACTH in the mammalian nervous system. 2019 , 111, 147-193	4
78	Efficacy and Practicality of Opioid Therapy in Japanese Chronic Noncancer Pain Patients. 2019 , 20, 222-231	0
77	Consumption of Movantik (Naloxegol) results in detection of naloxone in the patient's urine evaluated by confirmatory urine drug testing. 2019 , 67, 48-53	2
76	Vitamin D and vitamin B deficiencies in patients with small intestinal carcinoid tumour: is opioid use disorder a confounding factor in the diagnosis?. 2019 , 12,	2
75	Metabolic and the Surgical Stress Response Considerations to Improve Postoperative Recovery. 2019 , 23, 33	17
74	Medication prescriptions in 322 motor functional neurological disorder patients in a large UK mental health service: A case control study. 2019 , 58, 94-102	9
73	Opioid-induced bowel dysfunction: suggestions from a multidisciplinary expert Board. <i>Supportive Care in Cancer</i> , 2019 , 27, 4083-4090	3-9 7
72	Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies. 2019 , 4, e000527	11
71	Physiological Response to Opioids. 2019 , 62, 11-21	3
70	Factors Related to Adherence to Opioids in Black Patients With Cancer Pain. 2019 , 57, 28-36	14
69	Constipation prevalence and fatigue severity in regular kratom (<i>Mitragyna speciosa</i> Korth.) users. 2019 , 24, 233-239	2

68	The Evolving Role of Long-Term Pharmacotherapy for Opioid-Induced Constipation in Patients Being Treated for Noncancer Pain. 2019 , 32, 558-567		2
67	Side effects from opioids used for acute pain after emergency department discharge. 2020 , 38, 695-701		14
66	Retrospective evaluation of risk factors and treatment outcome predictors in cats presenting to the emergency room for constipation. 2020 , 22, 153-160		5
65	Can adequate analgesia be achieved in patients with cirrhosis without precipitating hepatic encephalopathy? A prospective study. <i>Clinical and Experimental Hepatology</i> , 2020 , 6, 243-252	2.2	1
64	Opioid-induced Constipation: A Review of Health-related Quality of Life, Patient Burden, Practical Clinical Considerations, and the Impact of Peripherally Acting μ Opioid Receptor Antagonists. <i>Clinical Journal of Pain</i> , 2020 , 36, 716-722	3.5	9
63	Opioid use is associated with incomplete capsule endoscopy examinations: a systematic review and meta-analysis. <i>Translational Gastroenterology and Hepatology</i> , 2020 , 5, 5	5.2	0
62	The Use of Peripheral μ Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety. <i>Drug Design, Development and Therapy</i> , 2020 , 14, 1009-1025	4.4	22
61	The impact of opioid use on human and health care costs in surgical patients. <i>Surgery Open Science</i> , 2020 , 2, 92-95	1.2	
60	Constipation screening in people taking clozapine: A diagnostic accuracy study. <i>Schizophrenia Research</i> , 2020 , 220, 179-186	3.6	11
59	Association between rectal douching and HIV acquisition: the mediating role of condom use and rectal bleeding in a national online sample of Chinese men who have sex with men. <i>Sexually Transmitted Infections</i> , 2021 , 97, 69-74	2.8	
58	Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis. <i>BMJ Supportive and Palliative Care</i> , 2021 , 11, 25-31	2.2	5
57	Delphi consensus on strategies in the management of opioid-induced constipation in cancer patients. <i>BMC Palliative Care</i> , 2021 , 20, 1	3	9
56	Constipation. 2021 , 1229-1264		0
55	Safety and efficacy of oxycodone in cancer patients with moderate-to-severe cancer pain: A single-medical center experiences. <i>Journal of Cancer Research and Practice</i> , 2021 , 8, 13	0.4	
54	Illegale Drogen: Welche Arten gibt es und was sind ihre Eigenschaften?. 2021 , 71-103		
53	The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies. <i>Supportive Care in Cancer</i> , 2021 , 29, 5209-5218	3.9	0
52	One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study. <i>BMJ Supportive and Palliative Care</i> , 2021 ,	2.2	1
51	Epidural analgesia for reduction of postoperative systemic opioid use following selective dorsal rhizotomy in children. <i>Journal of Neurosurgery: Pediatrics</i> , 2021 , 1-6	2.1	

50	Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel. <i>Advances in Therapy</i> , 2021 , 38, 3589-3621	4.1	5
49	Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology. <i>Pharmacology & Therapeutics</i> , 2021 , 230, 107961	13.9	5
48	Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry. <i>Pain Management</i> , 2021 ,	2.3	1
47	Dysfunction of the Bowel/Constipation. 2012 , 221-244		1
46	Medications Development for Treatment of Opioid Use Disorder. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021 , 11,	5.4	7
45	The role of drugs in bone pain. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2016 , 13, 93-96		9
44	Pain Management in Weight Loss Surgery: Aiming for Multimodal Approach. <i>Advances in Obesity Weight Management & Control</i> , 2016 , 5,	0.3	2
43	[Pain and opioids]. <i>Orvosi Hetilap</i> , 2008 , 149, 2363-70	0.8	6
42	Pharmacoeconomic Impact of Adverse Events of Long-Term Opioid Treatment for the Management of Persistent Pain. <i>Clinical Drug Investigation</i> , 2010 , 1	3.2	2
41	Preoperative albumin levels predict prolonged postoperative ileus in gastrointestinal surgery. <i>World Journal of Gastroenterology</i> , 2020 , 26, 1185-1196	5.6	6
40	Management of constipation. <i>Journal of Gerontological Nursing</i> , 2012 , 38, 9-15	1.2	7
39	A Review of Potential Adverse Effects of Long-Term Opioid Therapy: A Practitioner's Guide. <i>primary care companion for CNS disorders, The</i> , 2012 , 14,	1.2	95
38	Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015 , 53, 838-46	2	13
37	Avicenna's View on the Etiologies of Intestinal Obstruction. <i>Iranian Red Crescent Medical Journal</i> , 2016 , 18, e20034	1.3	3
36	Comprehensive Management of Cancer Pain Including Surgery. 2009 , 2061-2080		
35	Les antagonistes périphériques des opiacés. <i>Revue Internationale De Soins Palliatifs</i> , 2010 , 25, 113	0.1	
34	Constipation. 2012 , 337-350		
33	Opioid Adverse Effects and Opioid-Induced Hypogonadism. 2013 , 111-118		1

32 Nutrition in Palliative Care. **2013**, 137-161

31 Opioid-Induced Constipation. 190-197

30 Opioid Adverse Effects and Opioid-Induced Hypogonadism. **2015**, 111-118

29 Opioids in Abdominal Pain. **2015**, 135-142

28 The Epidemiology of Chronic Abdominal Pain. **2015**, 13-24

27 Differential Gastrointestinal Effects of Who-Step III Opioids in Low Back Pain Patients with vs. Without Constipation: Post-Hoc Analysis of Data from a 12-Week Prospective, Open-Label Blinded Endpoint Streamlined Study. *Global Journal of Anesthesiology*, 037-051 ○

26 Effect of intravenous acetaminophen on post-operative opioid-related complications: study protocol for a randomized, placebo-controlled trial. *Asia Pacific Journal of Clinical Trials Nervous System Diseases*, **2016**, 1, 154 ○.3

25 Ileus and Gastrointestinal Complications. **2017**, 339-346

24 The role of oxycodone/naloxone in pain management. *BMJ* **2017**, 17, 26-40 ○

23 A Rare Case of Adult Onset Intussusception Complicated By Narcotic Dependence. *Cureus*, **2017**, 9, e9641.2

22 Clinical practice evaluation of opioids induced constipation management in patients with cancer: The EIO-50 project. *Open Journal of Pain Medicine*, 034-040 ○

21 Analysis of care for cancer patients with opioid-induced constipation in clinical practice: EIO-PRAXIS Project. *Open Journal of Pain Medicine*, **2019**, 3, 027-033 ○

20 Constipation. **2020**, 1-37

19 Oxymorphone Extended-Release Tablets (Opana ER) For the Management of Chronic Pain: A Practical Review for Pharmacists. *P and T*, **2010**, 35, 324-57 1.4 2

18 Utilization of methylnaltrexone (relistor) for opioid-induced constipation in an oncology hospital. *P and T*, **2011**, 36, 33-6 1.4 3

17 A review of the clinical manifestations, pathophysiology and management of opioid bowel dysfunction and narcotic bowel syndrome. *Middle East Journal of Digestive Diseases*, **2014**, 6, 5-12 1.1 6

16 Prevalence of narcotic bowel syndrome in opioid abusers in iran. *Middle East Journal of Digestive Diseases*, **2014**, 6, 208-13 1.1 4

15 Economic burden of opioid-induced constipation among long-term opioid users with noncancer pain. *American Health and Drug Benefits*, **2015**, 8, 93-102 1.7 37

14	Increased Burden of Healthcare Utilization and Cost Associated with Opioid-Related Constipation Among Patients with Noncancer Pain. <i>American Health and Drug Benefits</i> , 2016 , 9, 160-70	1.7	14
13	Naldemedine for the Use of Management of Opioid Induced Constipation. <i>Psychopharmacology Bulletin</i> , 2020 , 50, 97-118	0.9	0
12	Risk Factors for Postoperative Ileus in Patients Undergoing Spine Surgery.. <i>Global Spine Journal</i> , 2022 , 21925682221075056	2.7	
11	Update S3-Leitlinie Intestinale Motilitätsstörungen: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM). <i>Zeitschrift Für Gastroenterologie</i> , 2022 , 60, 192-218	1.6	2
10	First-Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis. <i>Journal of Emergency Medicine</i> , 2021 ,	1.5	
9	A Case Report on Opioid-Induced Constipation in a Patient with Cancer Treated by <i>Jowiseunggi-tang</i>. <i>The Journal of Internal Korean Medicine</i> , 2022 , 43, 229-236	0.3	
8	EnhANCE Trial Protocol: A Multi-Centre, Randomised, Phase IV Trial Comparing the Efficacy of Oxycodone/Naloxone Prolonged Release (OXN PR) Versus Oxycodone Prolonged Release (Oxy PR) Tablets in Patients with Advanced Cancer. <i>SSRN Electronic Journal</i> ,	1	
7	Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis.		0
6	Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care. 2022 , 2022,		0
5	EnhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer. 2022 , 30, 101036		0
4	Management of Opioid-induced Constipation in Older Adults. 2023 , 57, 39-47		0
3	Antibiotic Knockdown of Gut Bacteria Sex-Dependently Enhances Intravenous Fentanyl Self-Administration in Adult Sprague Dawley Rats. 2023 , 24, 409		0
2	Pre-existing Opioid Use Worsens Outcomes in Patients With Diverticulitis. 2023 ,		0
1	Population pharmacokinetics of naloxegol in paediatric subjects receiving opioids.		0